基于随机对照试验的龙胆泻肝汤治疗高血压的meta分析

发布时间：2018-06-27 21:00

本文选题：龙胆泻肝汤 + 原发性高血压　；参考：《山东中医药大学》2016年硕士论文

【摘要】：研究目的:基于目前现有文献评价龙胆泻肝汤治疗高血压的证据水平,为撰写指南提供相应的证据。方法:根据系统评价要求,采取电子检索与手工检索相结合的方式系统检索中英文数据库、国内心血管系统疾病会议论文集及相关文章附录的参考文献,将最终纳入的文献进行Jadad评分,并使用Rev Man5.10对纳入文献进行分析。结果:(1)纳入的4篇文献经Jadad评分均为低质量文献。(2)龙胆泻肝汤单独使用时在降压疗效上无差别;但联合西药较单纯西药在降压疗效上有显著性差异;在改善症状、心功能(IVST、LVTWP、LVDD、LVMI、E/A、LVEF)上,龙胆泻肝汤治疗组有显著性差异;但在改善血脂及心率上无差别。(3)龙胆泻肝汤治疗组未表现出明确的不良反应。结论:龙胆泻肝汤联合西药治疗在降低患者血压,提高生活质量上体现出一定优势,应用三个月内也未发现有明显的不良反应。由于纳入研究数目有限,测量指标的不一致、疗效指标分布不均、随访时间不统一、缺乏长期随访时间不够长,证型辨证的缺乏及存潜存在的选择、发表偏倚的高度可能性,加之对不良反应的检测和报告不规范,因此,有关使用龙胆泻肝汤治疗原发性高血压的有效性和安全性尚不能得出确切结论,需要更多的高质量研究来支撑。
[Abstract]:Objective: to evaluate the evidence level of Longdan Xiegan decoction in the treatment of hypertension. Methods: according to the requirements of system evaluation, the Chinese and English databases, the proceedings of the domestic Conference on Cardiovascular Diseases and the references to the related articles were searched systematically by the combination of electronic and manual retrieval. Jadad score was used to evaluate the final included literature, and Rev Man5.10 was used to analyze the included literature. Results: (1) the Jadad scores of the four articles included were all of low quality. (2) there was no difference in the antihypertensive effect of Longdan Xiegan decoction alone, but there was significant difference in the antihypertensive effect between western medicine and western medicine alone, and in the improvement of symptoms, the cardiac function (IVSTL / LVTWPLVLVLVLVMIE / ALVEF), There was significant difference in the treatment group of Longdan Xiegan decoction, but there was no difference in improving blood lipid and heart rate. (3) the treatment group of Longdan Xiegan decoction showed no clear adverse reactions. Conclusion: Longdan Xiegan decoction combined with western medicine has some advantages in lowering blood pressure and improving quality of life. Due to the limited number of studies included, inconsistent measurement indicators, uneven distribution of therapeutic indicators, inconsistent follow-up time, lack of long term follow-up time, lack of syndrome differentiation and selection of latent symptoms and signs, high probability of publication bias. In addition, the detection and reporting of adverse reactions are not standardized. Therefore, the efficacy and safety of using Longdan Xiegan decoction in the treatment of essential hypertension can not reach an exact conclusion, and more high-quality research is needed to support it.
【学位授予单位】：山东中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】